What Remap Consulting does

Remap Consulting is a privately held, founder-owned pharmaceutical pricing and market access consultancy founded in January 2014 by Paul Craddy, who previously led diabetes pricing and market access for Takeda's EUCAN region. Headquartered in Zug, Switzerland (Remap Consulting GmbH) with a UK delivery hub in Alderley Park, Cheshire (Remap Consulting UK Ltd), the firm provides specialist advisory services to global pharmaceutical and biotechnology companies, including Amgen, Inventiva, Ipsen, Nestlé Health Science, and Krystal Biotechnology. The firm reports having worked with 161 pharma and biotech companies, including 11 of the top 20 global pharmaceutical companies, supported pricing and access strategies across 57 countries, and participated in over 60 pricing and reimbursement submissions across 25 countries.

The company's service portfolio is organized around three lines: Launch Implementation (pricing and reimbursement launch strategy, Joint Clinical Assessment support, Joint Scientific Consultation, HTA/payer early dialogue, payer value communication), Pricing (payer insights, pricing strategy, BD commercial assessments, tactical pricing including international reference price analysis), and Training (on-demand eLearning, interactive workshops, and visual training aids). The team of roughly 35-40 professionals carries extensive academic credentials (multiple PhDs from Oxford, Manchester, UCL, Imperial, Durham) and prior tenures at NICE, Pfizer, J&J, AbbVie, Takeda, GSK, Ferring, IQVIA, EY-Parthenon, Avalere Health, and PRMA Consulting. The firm has productized one AI-powered asset, the Remap JCA Advisor, a free knowledge retrieval tool that interprets EU HTA Regulation and Joint Clinical Assessment processes.

Revenue is generated on a professional services basis through bespoke consulting engagements and training delivery. The firm does not disclose pricing; engagements are project-based with bespoke scoping adapted to client needs. Go-to-market is predominantly direct enterprise sales supported by content-driven marketing, including a publication cadence of articles and webinars, active participation in industry conferences (ISPOR, HTAi, World Orphan Drug Congress), and strategic alliances with Medvance, EUCOPE, ISPOR, the Swiss Biotech Association, BHBIA, and Regulanet. Training is delivered with a stated 95% positive feedback rate. The firm holds a 2024 EcoVadis Silver Sustainability Rating and remains independently owned with no disclosed external institutional investment, no parent company, and no subsidiaries.

Name

Remap Consulting

Legal name

Remap Consulting GmbH

Website

https://remapconsulting.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Remap Consulting is a specialist pharmaceutical pricing and market access consultancy, founded in 2014 and headquartered in Zug, Switzerland, serving global pharma and biotech companies with launch strategy, HTA submissions, payer value communication, and training across 57 countries.

Ownership category

akta.pro rank

Product category

Pharmaceutical Market Access Consulting

NAICS

Management Consulting Services (54161)

SIC

Services-Management Consulting Services (8742)

akta.pro primary industry

Customer, Marketing & Sales Consulting (BPAHACAG)

akta.pro secondary industry

Operations & Process Improvement Consulting (BPAHACAB)

Keywords

• Pharmaceutical pricing
• Market access consulting
• Health technology assessment
• Value communication
• HTA submissions

Headquarters

HQ city

Zug

HQ country

Switzerland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Consulting Services: Professional consulting engagements providing pricing and market access strategy services to pharmaceutical and biotech companies. Engagements include launch strategy, HTA submissions, payer value communication, and training services. Revenue is generated through project-based consulting fees for strategic advisory work.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Remap Consulting is a specialist market access and pharmaceutical pricing consultancy that helps drug developers launch products, optimize pricing, and navigate health technology assessment (HTA) and reimbursement processes across global markets. The firm delivers bespoke consulting across launch strategy, payer value communication, pricing strategy, business development commercial assessments, and market access training for pharmaceutical and biotechnology clients. Services are supported by a free AI-powered tool, the Remap JCA Advisor, for navigating EU HTA regulation.

Product overview

Remap Consulting is a pricing and market access consultancy offering a comprehensive suite of services organized into three main areas: Launch (covering pricing/reimbursement strategy, Joint Clinical Assessment, Joint Scientific Consultation, HTA/payer early dialogue, and payer value communication), Pricing (encompassing payer insights, pricing strategy, BD commercial assessments, and tactical pricing), and Training (including on-demand eLearning, interactive workshops, and visual training aids). The firm also offers an AI-powered tool called the Remap JCA Advisor for navigating EU HTA processes. Services are delivered by a team of market access experts and are designed to help pharmaceutical and biotech companies optimize pricing and achieve successful market access.

Differentiator

Problem solved

Functional benefit

Products and services

• Launch Implementation Develops and implements pricing and market access launch strategies for pharmaceutical products, including support for global, regional, and local teams, HTA/pricing/reimbursement submissions, and payer scientific advice integration.
• Pricing & Reimbursement Launch Strategy Comprehensive strategy covering market access opportunity assessment, payer strategy development, HTA landscape assessments, indication sequencing optimization, clinical trial input optimization, and HTA/reimbursement submissions including NICE and EU Joint Clinical Assessments.
• Joint Clinical Assessment Expertise in EU HTA Joint Clinical Assessment process, including JCA dossier writing, PICO development, stakeholder liaison, and strategic guidance for navigating the pan-European clinical assessment process for drugs and medical devices.
• Joint Scientific Consultation Strategic guidance for engaging with HTA bodies under EU HTA Regulation, including strategic preparation for JSC submissions, stakeholder coordination, evidence generation advice, and post-JSC action planning.
• HTA & Payer Early Dialogue Formal and informal payer insights for clinical trial designs including Joint Scientific Consultations, NICE scientific advice, Office of Market Access engagement, payer scientific advice, early access opportunities, advisory boards, and payer insights research.
• Payer Value Communication Strategy Development of payer value communication materials including Global Value Dossiers, payer value driver identification, value message development, value story testing, objection handling, and formulary access tools.
• Payer Insights Utilizes an extensive global payer network to obtain payer research insights addressing pharma pricing and market access strategy needs, including pharmaceutical pricing research, Target Product Profile testing, value message testing, payer advisory boards, and mock payer negotiations.
• Pricing Strategy

Quantifiable outcome

• 95% positive feedback from training course participants
• +3 more outcomes

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature1 record

Partnerships

Six partnerships are on record, tiered core and minor.

• MedvancecoreStrategic or Co-development PartnerAs the UK partner for Medvance, Remap Consulting addresses the market access challenges of pharmaceutical companies in Great Britain. Medvance is a European-wide healthcare consultancy group.
• EUCOPEcoreStrategic or Co-development PartnerThe European Confederations of Pharmaceutical Entrepreneurs. Remap is an active member, presenter and regular contributor to EUCOPE, participating in industry discussions on pharmaceutical policy and market access.
• RegulanetminorStrategic or Co-development PartnerRemap is a member of regulanet®, providing pricing and market access expert insights to support members of regulanet® network.
• Swiss Biotech AssociationminorOthersAffiliation with the Swiss Biotech Association which represents the interests of the Swiss Biotech industry.
• BHBIAminorOthersThe industry association for thought leadership, professional development and ethical standards for deriving insights within UK healthcare.
• ISPORcoreOthersThe leading professional society for health economics and outcomes research (HEOR) globally. Remap participates in ISPOR events and conferences as presenters and attendees.

Scale indicators7 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Costello Medical: UK-based specialist pharma consultancy providing HTA submissions, market access, HEOR and value communications — directly comparable in service mix and target customer base to Remap.
• Putnam Associates: Boutique pharma strategy and market access consultancy with strong HTA/payer expertise — comparable in offering, customer type (global pharma), and boutique positioning.
• PRMA Consulting (now Avalere Health): Specialist pricing, market access and HEOR consultancy serving pharma and biotech — same core offering, same client set, and the firm where several Remap senior team members (e.g. Christina Baker, Nicole Lodowski) built their careers.
• Mtech Access: UK-based specialist market access consultancy focused on pricing, HTA submissions and payer engagement for pharma/biotech — directly comparable niche positioning to Remap.
• LCP Health Analytics: UK health economics and market access analytics consultancy — a specialist with comparable HTA/payer analytics focus (recent employer of Remap consultant Grace Miller).

Broad incumbents

• Evidera (PPD / Pharmaceutical Product Development): Large HEOR, market access and HTA consulting arm within PPD, providing value evidence, pricing and payer communications — same service envelope as Remap but inside a much larger CRO platform.
• IQVIA (formerly QuintilesIMS): Global life-sciences technology and consulting platform with market access and pricing practice — provides overlapping capabilities but as part of a much wider portfolio (Andrea Latour's previous employer).
• Charles River Associates (Life Sciences practice): Global consulting firm with dedicated Life Sciences practice covering pricing, market access and commercial strategy for pharma — broader portfolio but directly comparable pricing/market access service line.
• McCann Health (formerly McCann Complete Medical / FH): Global health communications and consulting group including FH/Real Chemistry providing market access, HEOR and value communications — overlaps with Remap's payer value communication work as part of a broader agency offering.

Regional players

• Syreon Research Institute: European HEOR and market access research institute covering HTA submissions, health economics and pricing research — comparable service offering with primary European focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/remap-consulting
• Xx.com/Remapconsulting
• Facebookfacebook.com/remapconsulting

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Remap Consulting